8-K filing — Aprea Therapeutics, Inc. (APRE)
Filed: 2026-08-28 AccNo: 0001104659-26-102795 Size: 182 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Aprea Therapeutics Expands Current Patent Portfolio
Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 28, 2026, 12:17 PM
- Checked
- Aug 28, 2026, 12:17 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $3
Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and lowers the price target from $6 to $3.
Read original at benzingaAprea Therapeutics Q2 EPS $(0.07) Beats $(0.23) Estimate
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.23) by 69.57 percent. This is a 86.79 percent increase over losses of $(0.53) per share
Read original at benzinga